SciClone Pharmaceuticals Story

SCLN -- USA Stock  

null 11.15  0.00  0.00%

Macroaxis does not monitor all media channels or aggregates social signals for SciClone Pharmaceuticals. But even though we do not provide professional-grade financial sentiment analysis on SciClone Pharmaceuticals, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for SciClone Pharmaceuticals. Also please take a look at World Market Map.
Sale by Hong Zhao of 12500 shares of SciClone Pharmaceuticals
Filed transaction by Sciclone Pharmaceuticals officer. General open market or private sale of non-derivative or derivative security

SciClone Pharmaceuticals Inc insider trading alert for sale of common stock by Hong Zhao, CEO China Operations, on January 3, 2018. This event was filed by Sciclone Pharmaceuticals with SEC on 2017-06-14. Statement of changes in beneficial ownership - SEC Form 4

Story Momentum

This story impact on price volatility cannot be determined at this time. Please check this story after some time to allow current data to be analyzed.

Similar stores for SciClone Pharmaceuticals

six days ago at finexaminer.com 
Analysts See -0.13 EPS for Soligenix, Inc. Plug Power Has 1.21 Sentiment - The FinExaminer
news
Analysts See -0.13 EPS for Soligenix, Inc. Plug Power Has 1.21 Sentiment The FinExaminerAnalysts expect Soligenix, Inc. to report -0.13 EPS on February, 8.After having -0.11 EPS previously, Soligenix, Inc.s analysts see 18.18 percent ...
over three months ago at MacroaxisInsider 
Purchase by Cavazza Claudio of 50000 shares of SciClone Pharmaceuticals
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals executive. General open market or private purchase of non-derivative or derivative security
over three months ago at MacroaxisInsider 
Purchase by Cavazza Paolo of 500 shares of SciClone Pharmaceuticals
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals executive. General open market or private purchase of non-derivative or derivative security
over three months ago at MacroaxisInsider 
Purchase by Essetifin Spa of 6900 shares of SciClone Pharmaceuticals
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals executive. General open market or private purchase of non-derivative or derivative security
over three months ago at MacroaxisInsider 
SciClone Pharmaceuticals exotic insider transaction detected
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals executive. Unconventional Insider trading
over three months ago at MacroaxisInsider 
Sale by Friedhelm Blobel of 100 shares of SciClone Pharmaceuticals
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals director. General open market or private sale of non-derivative or derivative security
over three months ago at MacroaxisInsider 
Acquisition by Hong Zhao of 12000 shares of SciClone Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)
over three months ago at bharatapress.com 
Insider Trading salesforce.com, inc. Insider Sold 824629.50 in Stocks
news
BharataPressFull coverage
over three months ago at MacroaxisInsider 
Exercise of in-the-money or at-the-money derivative position by Essetifin Spa of 5000 shares of SciClone Pharm...
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals executive. Derivative codes exercise of in-the-money or at-the-money derivative security
over three months ago at MacroaxisInsider 
Exercise or conversion by Friedhelm Blobel of 5301 shares of SciClone Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
over three months ago at MacroaxisInsider 
Sale by Friedhelm Blobel of 4793 shares of SciClone Pharmaceuticals
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals director. General open market or private sale of non-derivative or derivative security
over three months ago at MacroaxisInsider 
Purchase by Cavazza Paolo of 16684 shares of SciClone Pharmaceuticals
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals executive. General open market or private purchase of non-derivative or derivative security
over six months ago at MacroaxisInsider 
Acquisition by Woodman Dean S of 30000 shares of SciClone Pharmaceuticals subject to Rule 16b-3
Macroaxis News
Filed transaction by Sciclone Pharmaceuticals director. Grant, award or other acquisition pursuant to Rule 16b-3

Cash per Share

Cash per Share Comparative Analysis

  Cash per Share 
      SciClone Pharmaceuticals Comparables 
SciClone Pharmaceuticals is currently under evaluation in cash per share category among related companies. Cash per Share is a ratio of current cash on hands or in the banks of the company to total number of shares outstanding. It is used to determine firm's liquidity and is a good indicator of overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Also please take a look at World Market Map. Please also try Portfolio Manager module to state of the art portfolio manager to monitor and improve performance of your invested capital.
Search macroaxis.com